Ad is loading...
AUTL
Price
$3.08
Change
+$0.07 (+2.33%)
Updated
Nov 15 closing price
114 days until earnings call
XBIO
Price
$3.69
Change
+$0.03 (+0.82%)
Updated
Nov 15 closing price
Ad is loading...

AUTL vs XBIO

Header iconAUTL vs XBIO Comparison
Open Charts AUTL vs XBIOBanner chart's image
Autolus Therapeutics
Price$3.08
Change+$0.07 (+2.33%)
Volume$2.71M
CapitalizationN/A
Xenetic Biosciences
Price$3.69
Change+$0.03 (+0.82%)
Volume$2.7K
CapitalizationN/A
AUTL vs XBIO Comparison Chart
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
AUTL vs. XBIO commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a Hold and XBIO is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (AUTL: $3.08 vs. XBIO: $3.69)
Brand notoriety: AUTL and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 188% vs. XBIO: 12%
Market capitalization -- AUTL: $819.57M vs. XBIO: $5.69M
AUTL [@Biotechnology] is valued at $819.57M. XBIO’s [@Biotechnology] market capitalization is $5.69M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 0 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).

  • AUTL’s FA Score: 0 green, 5 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, XBIO is a better buy in the long-term than AUTL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 4 TA indicator(s) are bullish while XBIO’s TA Score has 2 bullish TA indicator(s).

  • AUTL’s TA Score: 4 bullish, 6 bearish.
  • XBIO’s TA Score: 2 bullish, 5 bearish.
According to our system of comparison, AUTL is a better buy in the short-term than XBIO.

Price Growth

AUTL (@Biotechnology) experienced а -17.43% price change this week, while XBIO (@Biotechnology) price change was -1.86% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

AUTL is expected to report earnings on Mar 11, 2025.

XBIO is expected to report earnings on Aug 11, 2023.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUTL($820M) has a higher market cap than XBIO($5.69M). XBIO YTD gains are higher at: 6.953 vs. AUTL (-52.174). XBIO has higher annual earnings (EBITDA): -5.01M vs. AUTL (-162.54M). AUTL has more cash in the bank: 706M vs. XBIO (7.3M). XBIO has less debt than AUTL: XBIO (153K) vs AUTL (50M). AUTL has higher revenues than XBIO: AUTL (10.5M) vs XBIO (2.52M).
AUTLXBIOAUTL / XBIO
Capitalization820M5.69M14,411%
EBITDA-162.54M-5.01M3,246%
Gain YTD-52.1746.953-750%
P/E RatioN/AN/A-
Revenue10.5M2.52M417%
Total Cash706M7.3M9,673%
Total Debt50M153K32,680%
FUNDAMENTALS RATINGS
AUTL vs XBIO: Fundamental Ratings
AUTL
XBIO
OUTLOOK RATING
1..100
6327
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
17
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
8948
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XBIO's Valuation (17) in the Biotechnology industry is in the same range as AUTL (41). This means that XBIO’s stock grew similarly to AUTL’s over the last 12 months.

XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AUTL (100). This means that XBIO’s stock grew similarly to AUTL’s over the last 12 months.

XBIO's SMR Rating (95) in the Biotechnology industry is in the same range as AUTL (96). This means that XBIO’s stock grew similarly to AUTL’s over the last 12 months.

XBIO's Price Growth Rating (48) in the Biotechnology industry is somewhat better than the same rating for AUTL (89). This means that XBIO’s stock grew somewhat faster than AUTL’s over the last 12 months.

XBIO's P/E Growth Rating (100) in the Biotechnology industry is in the same range as AUTL (100). This means that XBIO’s stock grew similarly to AUTL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUTLXBIO
RSI
ODDS (%)
Bullish Trend 3 days ago
84%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
79%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
83%
Advances
ODDS (%)
Bullish Trend 11 days ago
84%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
N/A
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
89%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
80%
N/A
View a ticker or compare two or three
Ad is loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HSZCX3.15-0.01
-0.32%
NexPoint Climate Tech C
HFECX42.97-0.57
-1.31%
Janus Henderson European Focus C
BBTLX14.90-0.20
-1.32%
Bridge Builder Tax Managed Large Cap
DDDAX21.61-0.31
-1.41%
13D Activist A
MREGX14.00-0.29
-2.03%
BlackRock Unconstrained Equity R

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with ACLX. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
+2.33%
ACLX - AUTL
37%
Loosely correlated
-7.63%
CABA - AUTL
36%
Loosely correlated
-19.84%
VCYT - AUTL
36%
Loosely correlated
-2.97%
GOSS - AUTL
34%
Loosely correlated
-3.88%
PLRX - AUTL
34%
Loosely correlated
-3.27%
More

XBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, XBIO has been loosely correlated with SYRE. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if XBIO jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBIO
1D Price
Change %
XBIO100%
+0.82%
SYRE - XBIO
34%
Loosely correlated
-6.62%
VXRT - XBIO
29%
Poorly correlated
-7.92%
EDSA - XBIO
29%
Poorly correlated
-4.55%
CDTX - XBIO
28%
Poorly correlated
-0.76%
AUTL - XBIO
27%
Poorly correlated
+2.33%
More